Lew Cantley (Cornell)
November 11, 2021 10:07 AM ESTUpdated 11:00 AM
R&D

Scoop: Famed can­cer re­searcher — and biotech founder — Lew Cant­ley is head­ed to Dana-Far­ber

John Carroll

Editor & Founder

Lew Cant­ley, the famed can­cer re­searcher best known for his dis­cov­ery of the PI3K path­way and his ground­break­ing work on can­cer me­tab­o­lism, is head­ed to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times